Sloan-kettering Institute for Cancer Research

Abbott Laboratories Corporation

David W Golde

David B Agus

Juan C Vera

Helen H Lee

Emerson W Chan

Priscilla Swanson

Mark H Buytendorp

John E Stephens

Bryan Peterson

Joseph D Rosenblatt

Kenneth B Idler

Joan E Johnson

Cheryl T Motley

Michelle Edwards

Eugene Robertson

Peggy Guidinger

Cynthia Tate

Irvin S Y Chen

This invention provides a method for increasing the concentration of ascorbic acid in the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's cells. This invention further provides a method for increasing the antioxidant potential of the cells of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the antioxidant potential of the subject's cells. This invention also provides a method for increasing the concentration of ascorbic acid in brain tissue of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in the subject's brain tissue. This invention also provides a method for increasing the antioxidant potential of brain tissue of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the antioxidant potential of the subject's brain tissue.

Method for increasing the concentration of ascorbic acid in brain tissues of a subject

This invention provides a method for increasing the ascorbic acid concentration in brain tissues of a subject which comprises administering to the subject an amount of dehydroascorbic acid effective to increase the concentration of ascorbic acid in brain tissues. This invention also provides that the dehydroascorbic acid enters the tissues through the facilitative glucose transporter.

Method for increasing the concentration of ascorbic acid in brain tissue of a subject

The present invention relates generally to a novel human T-cell lymphotropic, or leukemia, virus type II (HTLV-II) isolate designated NRA. HTLV-II was originally isolated from a patient with atypical hairy cell leukemia. Preliminary restriction analysis of this isolate demonstrated that it differs genetically from the prototypical HTLV-II isolate Mo. HTLV-II proviral molecular clones were obtained and the entire nucleotide sequence of the virus ascertained. The claimed invention is particularly directed toward the gp46 and p21 envelope proteins encoded by the env gene. Methods and kits for the detection of HTLV-II antibodies employing these envelope proteins are also described.

Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides

Growing community of inventors

New York, NY, United States of America

David W Golde